TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12706200

Group type: EXPERIMENTAL
Intervention: Low-frequency ultrasound (US) at low intensity (0 micro m) with HAES 0.1%, 1%, or 2%
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Low-frequency ultrasound (US) at medium intensity (144 micro m) with HAES 0.1%, 1%, or 2%
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Low-frequency ultrasound (US) at high intensity (192 micro m) with HAES 0.1%, 1%, or 2%
Number of subjects: 3

Group type: COMPARATOR
Intervention: Low-frequency ultrasound (US) at none intensity (0 micro m) with normal saline
Number of subjects: 3
Study: 10714840

Group type: EXPERIMENTAL
Intervention: Intraperitoneal lidocaine (200 mg in 200 ml saline)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (200 ml saline)
Number of subjects: 50
Study: 8833706

Group type: COMPARATOR
Intervention: Saline infusion (TU I)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Saline with amino acids infusion (TU II)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Saline with heparin infusion (TU III)
Number of subjects: 10
Study: 1435158

Group type: COMPARATOR
Intervention: Round chainring
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Shimano Biopace
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Eng10 elliptical chainring
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Eng90 elliptical chainring
Number of subjects: 11
Study: 2485264

Group type: EXPERIMENTAL
Intervention: Borderline hypertensive group
Number of subjects: 29

Group type: COMPARATOR
Intervention: Resting baroreflex sensitivity
Number of subjects: 29
Study: 31471173

Group type: EXPERIMENTAL
Intervention: Alternate Day Fasting (ADF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 29504981

Group type: EXPERIMENTAL
Intervention: Decision support tool linked to digital clinical history
Number of subjects: 287

Group type: COMPARATOR
Intervention: Standard care (Control group)
Number of subjects: 287
Study: 26960245

Group type: EXPERIMENTAL
Intervention: 5 μg tiotropium (2 puffs of 2.5 μg)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: 2.5 μg tiotropium (2 puffs of 1.25 μg)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Placebo (2 puffs)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Both tiotropium doses
Number of subjects: 398
Study: 25034562

Group type: EXPERIMENTAL
Intervention: Ustekinumab (180 mg at week 0 followed by 90 mg every 8 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Golimumab (200 mg at week 0 followed by 100 mg every 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Golimumab
Number of subjects: 0
Study: 23144826

Group type: EXPERIMENTAL
Intervention: Disulfiram (250 mg/d)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 20439572

Group type: EXPERIMENTAL
Intervention: Herpes zoster vaccine
Number of subjects: 38546

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38546
Study: 18494970

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (Kuraray)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Adper Single Bond 2 (3M ESPE)
Number of subjects: 1
Study: 16555581

Group type: EXPERIMENTAL
Intervention: pioglitazone (15 mg/day)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 mg/day)
Number of subjects: 91
Study: 12439788

Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg once-daily + diet
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg once-daily + diet
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo + diet
Number of subjects: 251
Study: 10051730

Group type: EXPERIMENTAL
Intervention: Good slides (<20% squamous cells and >50% viability; n = 24)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Low viability slides (<50% viability; n = 10)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: High squamous cell contamination slides (>20% squamous cells; n = 8)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Overall assessment of all slides
Number of subjects: 38
Study: 7655389

Group type: EXPERIMENTAL
Intervention: DNAemia detection by semi-nested PCR
Number of subjects: 162

Group type: COMPARATOR
Intervention: Viremia detection using shell vial assay
Number of subjects: 162
Study: 1971591

Group type: EXPERIMENTAL
Intervention: Xamoterol, 200 mg b.d.
Number of subjects: 178

Group type: COMPARATOR
Intervention: Digoxin, 0.125 mg b.d. or t.d.
Number of subjects: 178
Study: 7198463

Group type: EXPERIMENTAL
Intervention: Plafibride (1600 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA, 1600 mg/d)
Number of subjects: 0
Study: 31282782

Group type: EXPERIMENTAL
Intervention: Combined Z-palatopharyngoplasty (ZPPP) and partial glossectomy via 70-degree endoscopy-assisted coblation (Eco-TBR)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Multi-level surgery group
Number of subjects: 22
Study: 28114246

Group type: EXPERIMENTAL
Intervention: BB-12-supplemented yogurt
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonsupplemented control yogurt
Number of subjects: 60
Study: 25446409

Group type: EXPERIMENTAL
Intervention: Volar locking plates (VP)
Number of subjects: 74

Group type: COMPARATOR
Intervention: External fixation (EF)
Number of subjects: 74
Study: 23504941

Group type: EXPERIMENTAL
Intervention: 10 min classroom-based activity break (Bizzy Break!)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no activity break)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Comparison of intervention and control groups
Number of subjects: 90
Study: 21355071

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19407228

Group type: EXPERIMENTAL
Intervention: Symptomatic intracranial arterial stenosis
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Stroke out of the territory of the symptomatic artery
Number of subjects: 569
Study: 17295723

Group type: EXPERIMENTAL
Intervention: Stress-induced craving
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alcohol cue-induced craving
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Stress exposure
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alcohol cue exposure
Number of subjects: 20
Study: 15661224

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m(2) on days 1 and 8 and carboplatin AUC 4 on day 1 every 21 days for up to six cycles
Number of subjects: 40
Study: 11903104

Group type: EXPERIMENTAL
Intervention: EEG in ARSwE group
Number of subjects: 78

Group type: COMPARATOR
Intervention: EEG abnormality
Number of subjects: 78

Group type: COMPARATOR
Intervention: EEG normality
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: EEG findings
Number of subjects: 78
Study: 10087798

Group type: EXPERIMENTAL
Intervention: Autogenic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study: 7784970

Group type: EXPERIMENTAL
Intervention: Ceruloplasmin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2112616

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (50 mg on day 3 and 25 mg on day 6)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7451151

Group type: EXPERIMENTAL
Intervention: Penicillin and probenecid (4 million IU depot penicillin i.m. + 1 g probenecid orally)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Probenecid given 30 min prior to penicillin administration
Number of subjects: 19
Study: 31365792

Group type: EXPERIMENTAL
Intervention: All‐Bond UniversalTM 2‐component adhesive
Number of subjects: 56

Group type: COMPARATOR
Intervention: ScotchbondTM Universal single‐component adhesive
Number of subjects: 56
Study: 28500554

Group type: EXPERIMENTAL
Intervention: CPT + TD
Number of subjects: 71

Group type: COMPARATOR
Intervention: TD
Number of subjects: 71
Study: 26341878

Group type: EXPERIMENTAL
Intervention: Pregabalin (75 mg) plus control treatment (acetaminophen, 400 mg, and codeine phosphate powder, 20 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control treatment (acetaminophen, 400 mg, and codeine phosphate powder, 20 mg)
Number of subjects: 50
Study: 23633146

Group type: EXPERIMENTAL
Intervention: Doxylamine hydrogen succinate 12.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Doxylamine hydrogen succinate 25 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Doxylamine hydrogen succinate 12.5 mg vs 25 mg
Number of subjects: 12
Study: 21307137

Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (ExQW) 2 mg for 24 weeks
Number of subjects: 252

Group type: COMPARATOR
Intervention: Exenatide twice daily (ExBID) 5 μg for 4 weeks followed by 10 μg for 20 weeks
Number of subjects: 252
Study: 19824074

Group type: EXPERIMENTAL
Intervention: Lead-in nonresponders (346 patients)
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Breakthrough/relapse patients (78 patients)
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Express patients (111 patients)
Number of subjects: 535

Group type: COMPARATOR
Intervention: Maintenance therapy with low-dose peginterferon
Number of subjects: 535
Study: 16895823

Group type: EXPERIMENTAL
Intervention: Group I (assessments at 4 weeks preoperatively, on the day of surgery, and 2 weeks and 12 months postoperatively)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group II (assessments at 2 weeks and 12 months postoperatively)
Number of subjects: 0
Study: 15265162

Group type: EXPERIMENTAL
Intervention: oral alfacalcidol 0.25 microg daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: oral alendronate 5 mg daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: nasal spray calcitonin 200 IU/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study: 10878728

Group type: EXPERIMENTAL
Intervention: Medical record DI (MDI) scoring
Number of subjects: 60

Group type: COMPARATOR
Intervention: Direct DI (DDI) scoring
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MDI organ system scores
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MDI and DDI total scores comparison
Number of subjects: 60
Study: 9365147

Group type: EXPERIMENTAL
Intervention: 0.5 mg glyceryl trinitrate
Number of subjects: 20
Study: 1804605

Group type: EXPERIMENTAL
Intervention: Nylestriol 2 mg every 2 weeks for 1 year
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nylestriol 2 mg every 2 weeks for 1 year with medroxyprogesterone acetate 6 mg daily for 7 days at the end of treatment
Number of subjects: 90
Study: 6321282

Group type: EXPERIMENTAL
Intervention: Oat bran 18 g/day
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo 18 g/day
Number of subjects: 6
Study: 31655571

Group type: EXPERIMENTAL
Intervention: Community-based aftercare intervention involving two meetings with a mental health clinician and follow-up contacts by peer workers for four weeks (with an option to extend to 12 weeks).
Number of subjects: 1340

Group type: EXPERIMENTAL
Intervention: Community-based aftercare intervention.
Number of subjects: 1340

Group type: COMPARATOR
Intervention: Treatment-as-usual control.
Number of subjects: 1340
Study: 27876358

Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (IVIG; 400mg/kg/day for 5 days)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 26941024

Group type: EXPERIMENTAL
Intervention: Resistance training (RT) for 8 weeks
Number of subjects: 57

Group type: COMPARATOR
Intervention: Sedentary lifestyle (Control)
Number of subjects: 57
Study: 25802345

Group type: EXPERIMENTAL
Intervention: Vitamin B-12 supplementation
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Combination of vitamin B-12 and folic acid
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 23232095

Group type: EXPERIMENTAL
Intervention: 700 mg (four tablets) single dose
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 700 mg 12‐hourly x two doses
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 1,400 mg (eight tablets) single dose
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 121
Study: 20044155

Group type: EXPERIMENTAL
Intervention: Physical training and nutritional intervention program
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Nutrition intervention
Number of subjects: 96
Study: 18551121

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (0.05 g/kg fat-free mass)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline (placebo control)
Number of subjects: 11
Study: 16491653

Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acid mixture of omega-3 and -6
Number of subjects: 0
Study: 12455450

Group type: EXPERIMENTAL
Intervention: Methimazole (10-20 mg per day)
Number of subjects: 127
Study: 10483893

Group type: EXPERIMENTAL
Intervention: TPN with oral glutamine supplementation of 30 g/d
Number of subjects: 15

Group type: COMPARATOR
Intervention: TPN with conventional glutamine-free amino acid solution
Number of subjects: 15

Group type: COMPARATOR
Intervention: Oral intake of normal food
Number of subjects: 15
Study: 8738682

Group type: EXPERIMENTAL
Intervention: Combination of paracetamol 800 mg plus codeine 60 mg
Number of subjects: 108

Group type: COMPARATOR
Intervention: Paracetamol 1000 mg
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 1683338

Group type: EXPERIMENTAL
Intervention: Zotepine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study: 333516

Group type: EXPERIMENTAL
Intervention: Oral prostaglandin E2
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30502569

Group type: EXPERIMENTAL
Intervention: Kinesthetic ability trainer (KAT 2000) training group (Group 1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Flamingo training group (Group 2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined training group (Group 3)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study: 28036322

Group type: EXPERIMENTAL
Intervention: Femoral rotational taping
Number of subjects: 24
Study: 26121679

Group type: EXPERIMENTAL
Intervention: HIV-DNA ID with Electroporation (EP)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: HIV-DNA ID without Electroporation (EP)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: HIV-MVA or HIV-MVA+gp140
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: HIV-DNA ID with or without EP
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: HIV-MVA+/−gp140
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 23330658

Group type: EXPERIMENTAL
Intervention: Candesartan 4 mg/day
Number of subjects: 108

Group type: COMPARATOR
Intervention: Amlodipine 2.5 mg/day
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Switching from other ARBs to Candesartan
Number of subjects: 108
Study: 21665105

Group type: EXPERIMENTAL
Intervention: Device (holographic technology wristband)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (silicone wristband with stainless steel discs)
Number of subjects: 42
Study: 19309197

Group type: EXPERIMENTAL
Intervention: Continuation-phase cognitive therapy (C-CT)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Assessment control
Number of subjects: 84
Study: 22926596

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 316

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316
Study: 16050407

Group type: EXPERIMENTAL
Intervention: Blockers of the renin-angiotensin system (RAS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strict control of blood pressure (PA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Administration of RAS blockers in presence of microalbuminuria
Number of subjects: 0
Study: 12853792

Group type: EXPERIMENTAL
Intervention: 180 mmol (3%) ALA administered for 6 hours
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 8 mmol (0.2%) HAL administered for 4 hours
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 8 mmol HAL administered for 2 hours followed by 2 hours of resting time (2+2 hours concept)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Topical administration of HAL
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Topical administration of ALA or HAL
Number of subjects: 18
Study: 10217357

Group type: EXPERIMENTAL
Intervention: 85% concentrate of omega-3 fatty acids (Omacor)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Untreated normolipidemic subjects
Number of subjects: 40
Study: 7573813

Group type: EXPERIMENTAL
Intervention: Modified nasal lavage technique after unilateral antigen challenge
Number of subjects: 20
Study: 2696390

Group type: EXPERIMENTAL
Intervention: Short course therapeutic regimen consisting of isoniazid, rifampicin, and pyrazinamide for the first two months, followed by isoniazid and rifampicin for the next four months.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Classical therapy consisting of isoniazid and rifampicin for a nine-month period.
Number of subjects: 50
Study: 851042

Group type: EXPERIMENTAL
Intervention: 47 mm² electrode
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 6 mm² electrode
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: New large contact area-small active surface electrode
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Impulse duration of 2 msec
Number of subjects: 94
Study: 12395952

Group type: EXPERIMENTAL
Intervention: Provider advice to quit smoking
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Annual Papanicolaou test in the prior 3 years
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Readiness to quit smoking
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Nicotine dependence
Number of subjects: 432
Study: 29722425

Group type: EXPERIMENTAL
Intervention: Indocyanine green-based photodynamic therapy
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Indocyanine green-based photodynamic therapy with 805-nm diode laser
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Indocyanine green-based photodynamic therapy with 830-nm light-emitting diode
Number of subjects: 21

Group type: COMPARATOR
Intervention: Methyl aminolevulinate-based photodynamic therapy
Number of subjects: 21
Study: 26763947

Group type: EXPERIMENTAL
Intervention: Isokinetic leg-press training with moderate vibration (n=26)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Functional physiotherapy (n=29)
Number of subjects: 55
Study: 24562088

Group type: EXPERIMENTAL
Intervention: Attention Feedback Awareness and Control Training (A-FACT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Active placebo control condition
Number of subjects: 40
Study: 22547331

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 64
Study: 20299633

Group type: EXPERIMENTAL
Intervention: Quality of communication (QOC)
Number of subjects: 342
Study: 18566974

Group type: EXPERIMENTAL
Intervention: KW-6002 (istradefylline)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Cold KW-6002
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Daily oral doses of KW-6002 greater than 5 mg
Number of subjects: 2

Group type: COMPARATOR
Intervention: MRS 1745 (A(2B) receptor selective antagonist)
Number of subjects: 2
Study: 16227335

Group type: EXPERIMENTAL
Intervention: i.m. tramadol 100 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: famotidine 20 mg
Number of subjects: 60
Study: 11862087

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 100 mg orally, three times daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Topical steroid, topical antibiotic, and artificial tears
Number of subjects: 40
Study: 10549464

Group type: EXPERIMENTAL
Intervention: Group 1: propofol 2 mg kg‐1 and remifentanil 2 micrograms kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group 2: propofol 2 mg kg‐1, remifentanil 1 microgram kg‐1 and lignocaine 1 mg kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 7606988

Group type: EXPERIMENTAL
Intervention: Salmeterol, 50 micrograms twice a day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Albuterol, 400 micrograms four times a day
Number of subjects: 20
Study: 2297260

Group type: EXPERIMENTAL
Intervention: Bromocriptine added to cyclosporine, azathioprine, and prednisone
Number of subjects: 54

Group type: COMPARATOR
Intervention: Cyclosporine, azathioprine, and prednisone (control group)
Number of subjects: 54
Study: 348380

Group type: EXPERIMENTAL
Intervention: Ticrynafen
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 31234865

Group type: EXPERIMENTAL
Intervention: Single low-dose primaquine added to artemether-lumefantrine treatment
Number of subjects: 166

Group type: COMPARATOR
Intervention: Artemether-lumefantrine treatment without primaquine
Number of subjects: 166
Study: 28070970

Group type: EXPERIMENTAL
Intervention: Sunflower seed oil (SSO)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Baby lotion (L)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 50
Study: 26254819

Group type: EXPERIMENTAL
Intervention: New lingually based triangular flap
Number of subjects: 22

Group type: COMPARATOR
Intervention: Traditional triangular flap
Number of subjects: 22
Study: 23126384

Group type: EXPERIMENTAL
Intervention: montelukast (5 or 10 mg, once daily)
Number of subjects: 62

Group type: COMPARATOR
Intervention: salmeterol (50 μg, b.i.d.)
Number of subjects: 62
Study: 21439514

Group type: EXPERIMENTAL
Intervention: Tigecycline monotherapy
Number of subjects: 127

Group type: COMPARATOR
Intervention: Vancomycin-aztreonam
Number of subjects: 127
Study: 20077991

Group type: EXPERIMENTAL
Intervention: Res-Care Intervention (two-tiered motivational intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Future work recommendations
Number of subjects: 0
Study: 16426100

Group type: EXPERIMENTAL
Intervention: Modafinil (340 mg, N = 44; 425 mg, N = 82)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo (N = 64)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 190
Study: 14503435

Group type: EXPERIMENTAL
Intervention: Constraint-Induced Therapy (CI therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed intervention
Number of subjects: 0